Aromatase_Inhibitor.svg
Size of this PNG preview of this SVG file:
512 × 384 pixels
.
Other resolutions:
320 × 240 pixels
|
640 × 480 pixels
|
1,024 × 768 pixels
|
1,280 × 960 pixels
|
2,560 × 1,920 pixels
.
Summary
Description Aromatase Inhibitor.svg |
English:
Often used as a cancer treatment in postmenopausal women, aromatase inhibitors work by blocking the conversion of androstenedione and testosterone into estrone and estradiol, respectively, which are both crucial to the growth of developing breast cancers (aromatase inhibitors are also effective at treating ovarian cancer, but less commonly so). In the diagram, the adrenal gland (1) releases androstenedione (3) while the ovaries (2) secrete testosterone (4). Both hormones travel to peripheral tissues or a breast cell (5), where they would be converted into estrone (8) or estradiol (9) if not for aromatase inhibitors (7), which prevent the enzyme CYP19AI (also known as aromatase or estrogen synthase) (6) from catalyzing the reaction that turns androstenedione and testosterone into estrone and estradiol. In the diagram, Part A represents the successful conversion of androstenedione and testosterone into estrone and estradiol in the liver. Part B represents the blockage of this conversion by aromatase inhibitors both in peripheral tissues and in the breast tumor itself.
|
Date | |
Source | Own work |
Author | Ilovesquirrelz |
Licensing
I, the copyright holder of this work, hereby publish it under the following license:
This file is licensed under the
Creative Commons
Attribution-Share Alike 4.0 International
license.
-
You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
-
Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.